LWB1
Research LWB1 on Bullrun: market cap EUR 1.85B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLWB1
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.85B
- Financial periodFY2025
- RevenueUSD 17.20M
- Revenue growth191.4%
- Net income-USD 102.14M
- Free cash flow-USD 50.68M
- Gross margin70.2%
Valuation Snapshot
latest market cap is EUR 1.85B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 17.20M | -USD 102.14M | -USD 50.68M | 70.2% | -0.85 | USD 161.16M | USD 128.16M | USD 597.44M |
| FY2024 | USD 5.90M | -USD 87.96M | -USD 48.79M | 100.0% | -0.89 | USD 62.56M | USD 118.92M | USD 480.36M |
| FY2023 | USD 7.50M | -USD 81.89M | -USD 63.58M | 100.0% | -1.05 | USD 70.92M | USD 116.50M | USD 501.84M |
| FY2022 | USD 10.21M | -USD 91.35M | -USD 66.01M | n/a | -133.8 | USD 60.03M | USD 106.91M | USD 497.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 1.85B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About LWB1
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LWB1's market cap?
LWB1's market capitalization is EUR 1.85B.
What does LWB1 do?
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.